Heart failure with low output in HIV positive patient. Heart failure, unspecified
Conditions
Interventions
Intervention 1: Intervention group: In HIV-positive patients with heart failure, empagliflozin 10 mg, made in Iran, is added to other treatments including diuretics, beta-blockers, angiotensin inhibit
Mineralocorticoid antagonists and angiotensin enzyme inhibitors made in Iran are placed and followed up for one year.
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age >18YEARS HIV EF<50%
Exclusion criteria
Exclusion criteria: MALIGNANCY OR Opportunistic infection PREGNANCY CKD AND GFR<20
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the 6min walking test. Timepoint: The beginning of the study and six months later and the end of the study. Method of measurement: The patients walks in a 30-meter hall with maximum power and the time of the patient's shortness of breath is recorded, and the maximum walking time of the patient will be 6 minutes. | — |
Secondary
| Measure | Time frame |
|---|---|
| Improve cardiac output. Timepoint: Every 6 months. Method of measurement: Echocardiography.;Function class. Timepoint: Every 3months. Method of measurement: Examining the patient and asking about the degree of shortness of breath.;Lower limb edema. Timepoint: Every 3months. Method of measurement: Examination by a doctor.;Hospitalized cases. Timepoint: Every 3months. Method of measurement: Question from the patient.;Change PRO-BNP. Timepoint: EVERY 6 MONTHS. Method of measurement: LAB TEST.;Change in uric acid. Timepoint: Every 6months. Method of measurement: lab test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMarjan Hemmatian
Tehran University of Medical Sciences
Outcome results
None listed